SYNTHESIS, ANTITUMOR ACTIVITY, PHARMACOPHORE MODELING AND QSAR STUDIES OF NOVEL PYRAZOLES AND PYRAZOLO [1, 5-A] PYRIMIDINES AGAINST BREAST ADENOCARCINOMA MCF-7 CELL LINE

Authors

  • Magda M. F. Ismail
  • Dalia H. Soliman
  • Amel M. Farrag Department of Pharmaceutical Chemistry, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt
  • Rehab Sabour

Abstract

Objective: The present work aimed to synthesize New series of pyrazoles 3 and pyrazolo[1,5-a]pyrimidines 5, 7, 9 in order to evaluate their antiproliferative activity against human breast adenocarcinoma MCF-7cell line and study the cell cycle progression of the most active compounds. In addition, Pharmacophore modeling and QSAR Studies of these new compounds were done.

Methods: The diazonium salt of 4-aminoacetophenone 1 was coupled with malononitrile in ethanol using sodium acetate affords 2-[(4-acetylphenyl)diazenyl] malononitrile Cycloaddition of hydrazine hydrate, in molar ratios 1:1 or 1:2, on compound 2, furnished 3,5-diaminopyrazolederivatives 3a and 3b respectively. Moreover, new pyrazolo[1,5-a]pyrimidine derivatives 5a-f were obtained upon cyclocondensation of 3a, b with different chalcones 4a-c in EtOH/piperidine,while compounds 7a-f were prepared via cycloaddition of 3a, b with various arylidene malononitriles 6a-c in the same reaction condition. Finally, treatment of 3a, b with ethyl 2-cyano-3-ethoxyacrylate 8a or 2-(ethoxymethylene)malononitrile 8b in EtOH/TEA yielded the novel pyrazolo[1,5-a]pyrimidine derivatives 9a, b respectively. These target compounds were screened for their cytotoxic activity against MCF-7 (human breast Cell Line) followed by study cell cycle of 7a. Finally, Pharmacophore modeling and QSAR Studies was carried out.

Results: The pyrazolopyrimidine 7a was the most active compound (IC50 = 3.25 µM), whereas, some of the tested compounds exploited moderate growth inhibitory activity. Its effect was further studied on cell cycle progression; results showed that compound 7a induced cell cycle arrest at S-phase verifying this compound as a promising selective anticancer agent.

Conclusion: Compound 7a was found to be the most active member against MCF-7 breast cancer (IC50= 3.25 μM), Further biological assessment of 7a using flow-cytometric analysis, revealed that it induced cell cycle arrest at S phase.

Keywords: Pyrazole, Pyrazolo[1,5-a]pyrimidine, MCF-7 breast cancer cell line, Cell cycle profile, 3D pharmacophore,1 QSAR study

Downloads

Download data is not yet available.

References

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007;57:43-66.

David ET. Chemistry and pharmacology of anticancer drugs. 1st ed. Taylor and Francis group editor. New York: CRC PRESS; 2007.

Keshtgar M, Davidson T, Pigott K, Falzon M, Jones A. Current status and advances in the management of early breast cancer. Int J Surg 2010;8:199-202.

Maughan KL, Lutterbie MA, Ham PS. Treatment of breast cancer. Am Fam Physician 2010;81:1339–46.

Nahren MM, Nanda G. An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation-A case study with CDK2/Cyclin A. Eur J Med Chem 2008;43:2807-18.

Bronson J, Dhar M, Ewing W, Lonberg N. Chapter thirty-one – to market, to market-2011. Annu Res Med Chem 2012;47:548.

Ruth PF, Pilar G, José E. A review of recent progress (2002-2012) on the biological activities of pyrazoles. Arkivoc 2014;2:233-93.

Bronson J, Dhar M, Ewing W, Lonberg N. Annu Res Med Chem. 1st ed. Elsevier Inc; 2012.

Berger DM, Torres N, Dutia M, Powell D, Ciszewski G, Gopalsamy A, et al. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors. Bioorg Med Chem Lett 2009;19:6519–23.

Williamson DS, Parratt MJ, Bower JF, Moore JD, Richardson CM, Dokurno P, et al. Structure-guided design of pyrazolo[1,5-a] pyrimidines as inhibitors of the human cyclin-dependent kinase. J Bioorg Med Chem Lett 2005;15:863-7.

Li R, Ellen RL, Alex JB, Victoria D, Susan LG, Jonas Grina, et al. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties. Bioorg Med Chem Lett 2012;22:1165–8.

Al-Sehemi AG, Irfan A, Fouda AM. Synthesis, characterization and density functional theory investigations of the electronic, photophysical and charge transfer properties of donor–bridge–acceptor triaminopyrazolo[1,5-a]pyrimidine dyes. Spectrochim Acta Part A 2013;111:223–9.

Khurana JM, Kiran D, Susruta M. An efficient 1,3-allylic carbonyl transposition of chalcones. Monatsh Chem 2009;140:69-72.

Xiangâ€Shan W, Zhaoâ€Sen Z, Yuâ€Ling Li, Daâ€Qing S, Shuâ€Jiang Tu, Xianâ€Yong W, et al. Simple procedure for the synthesis of aryl methylene malononitrile without a catalyst. Synth Commun 2005;35:1915-20.

Claudia R, Renate D, Hans J, Heinz G. Possible rearrangements during the synthesis of di-and trisubstituted pyrazoles. Montash Chem 1998;129:1313-8.

Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.

Dominic AS, Robert HS, Kenneth DP, Anne M, Siobhan T, Thomas HN, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-33.

Adel SG, Jacek S, Nasser SM, Hanaa F. Synthesis and QSAR study of novel cytotoxic spiro[3H-indole-3,20(10H)-pyrrolo[3,4-c]pyrrole]-2,3`,5`(1H,2`aH,4`H)-triones. Eur J Med Chem 2012;47:312-22.

Saleh NM, Ammar YA, Micky JA, Abbas HA, EL-Gaby MS. Novel synthesis and antimicrobial investigation of pyrazolo[1,5-a]pyrimidine and pyrazolotriazine containing piperidinyl sulfone moiety. Indian J Chem 2004;43B:2195-202.

Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, et al. 4-Arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem 2006;49:6500-9.

El-Shafei A, Fadda AA, Khalil AM, Ameen TAE, Badria FA. Synthesis, antitumor evaluation, molecular modeling and quantitative structure-activity relationship (QSAR) of some novel arylazopyrazolo diazine and triazine analogs. Bioorg Med Chem 2009;17:5096–105.

Karcı F, Demircal A. Synthesis of disazopyrazolo[1,5-a]pyrimidines. Dyes Pigm 2007;74:288-97.

Fadda AA. Synthesis of some new arylazothiophene and arylazopyrazole derivatives as antitumor agents. Pharmacol Pharm 2012;3:148-57.

Tsai PC, Wang IJ. A facile synthesis of some new pyrazolo[1,5-a]pyrimidine heterocyclic disazo dyes and an evaluation of their solvatochromic behavior. Dyes Pigm 2007;74:578-84.

Dawane BS, Konda SG, Zangade SB. Design, synthesis, and characterization of some novel pyrazolo[1,5-a] pyrimidines as potent antimicrobial agents. J Heterocycl Chem 2010; 47:1250-4.

Elfahham HA, Elgemeie GH, Ibraheim YR, Elnagdi MH. Studies on 3,5-diaminopyrazoles: new routes for the synthesis of new pyrazoloazines and pyrazoloazoles. Liebigs Ann Chem 1988;8:819-22.

Hassan AS, Hafez TS, Osman SA, Ali MM. Synthesis and in vitro cytotoxic activity of novel pyrazolo[1,5-a]pyrimidines and related Schiff bases. Turk J Chem 2015;39:1102-13.

Published

01-07-2016

How to Cite

Ismail, M. M. F., D. H. Soliman, A. M. Farrag, and R. Sabour. “SYNTHESIS, ANTITUMOR ACTIVITY, PHARMACOPHORE MODELING AND QSAR STUDIES OF NOVEL PYRAZOLES AND PYRAZOLO [1, 5-A] PYRIMIDINES AGAINST BREAST ADENOCARCINOMA MCF-7 CELL LINE”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 7, July 2016, pp. 434-42, https://innovareacademics.in/journals/index.php/ijpps/article/view/11103.

Issue

Section

Original Article(s)